EFFECTIVE USE OF ANTIPLATELETS AFTER RECONSTRUCTIVE OPERATIONS

Treatment of chronic obliterating peripheral arterial disease (PAD) and the resulting chronic ischemia of the lower extremities is at the moment one of the most urgent problems in vascular surgery. According to recent reports, the prevalence of PAD has already reached the pandemic: in 2010, there were more than 200 million people suffering from PAD, including more than 40 million in Europe and over 14 million in North and South America. This disease is rarely found in patients younger than 40 years, but one person out of every 10 people aged 70 years or older and every sixth person at the age of 80 years or older suffers from it [1]. In the United States, there are more than 8.5 million people suffering from this disease. In this country among people older than 55 years 10% have an asymptomatic form of peripheral arterial diseases and 5% suffer from intermittent claudication (IC) [2]. In Russia, from 15 to 30% of the population older than 65 years have signs of obliterating diseases of lower limb arteries [3,  4]. In 2013, in 44 regions of Russia 173 883 new cases of PAD were registered, which given the high prevalence of asymptomatic forms of the disease (more than 2/3 of patients are asymptomatic) suggests that the number of this group of patients in Russia exceeds more than 1.5 million people.

1. Fowkes FG, Rudan D, Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet, 2013, 382(9901): 1329-40.

2. Go AS, Mozaffarian D, Roger VL et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation, 2014, 129(3): 399-410.

3. Cardiovascular diseases. Fact sheet#317, 2011. WHO Library Catalogung in Publication Data.

4. Национальные рекомендации по ведению пациентов с патологией артерий нижних конечностей. Ангиология и сосудистая хирургия (Приложение), 2013, 19(2): 1-675.

5. Norgen L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg, 2007, 33(Suppl 1).

6. Vogel TR, Dombrovskiy VY, Carson JL, et al. In-hospital and 30-day outcomes after tibioperoneal interventions in the US Medicare population with critical limb ischemia. Journal of vascular surgery, 2011, 54(1): 109-15.

7. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European heart journal. 2011, 32(22): 2851-90.

8. Abola MT, Bhatt DL, Duval S et al. Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis, 2012, 221(2): 527-35.

9. Mangiafico RA, Mangiafico M. Medical treatment of critical limb ischemia: current state and future directions. Current vascular pharmacology, 2011, 9(6): 658-76.

10. Conte MS, Geraghty PJ, Bradbury AW et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. Journal of vascular surgery, 2009, 50(6): 1462-73.

11. de Donato G, Gussoni G, de Donato G et al. The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery. Annals of surgery, 2006, 244(2): 185-93.

12. Goodney PP, Nolan BW, Schanzer A et al. Factors associated with amputation or graft occlusion one year after lower extremity bypass in northern New England. Annals of vascular surgery, 2010, 24(1): 57-6.

13. Korabathina R, Weintraub AR, Price LL et al. Twenty-year analysis of trends in the incidence and in-hospital mortality for lower-extremity arterial thromboembolism. Circulation, 2013, 128(2): 115-21.

14. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. The New England journal of medicine, 1992, 326(6): 381-6.

15. Покровский А.В. Клиническая ангиология. 2004. Т. 1: 35-36.

16. Покровский А.В., Ивандаев А.С. Состояние сосудистой хирургии в России в 2016 году. Ангиология и сосудистая хирургия, 2017: 5-44.

17. Rooke TW, Hirsch AT, Misra S et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiology, 2013, 61: 1555-70.

18. Bhatt D, Scheiman J, at all. ACCF/ACG/AHA 2008 Expert consensus Document on Reducing the Gastrointestinal Risks of Antplatelet Therapy. J Am Coll Card, 2008, 52(18): 1502-1517.

19. Толпыгина С.Н., Марцевич С.Ю., Хосева Е.Н. Эффективность и безопасность применения ацетилсалициловой кислоты в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Рациональная фармакотерапия в кардиологии, 2012, 8(2): 205-210.

20. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents forpreventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev, 2015, 2: CD000535.

21. Anderson JL, Halperin JL, Albert NM et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/ AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2013, 127(13): 1425-43.

22. Berger JS, Krantz MJ, Kittelson JM et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA, 2009, 301(18): 1909-19.

23. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a ran-domized controlled trial. JAMA, 2010, 303: 841–848.

24. Belch J еt al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 2008, 337: a1840.

25. Von Beckerath N, Kastrati A, Wieczorek A et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. European Heart Journal, 2007, 28: 1814-9.

26. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care, 2005, 28(8): 1981-1987.

27. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England journal of medicine, 2006, 354(16): 1706-17.

28. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug safety: an international journal of medical toxicology and drug experience, 2014, 37(4): 201-11

29. Subhash B. New Developments in Antiplatelet Therapies for Patients with Peripheral Artery Disease. J Am Coll Cardiology, 2016. www. http: //www.acc.org.

30. Anand S, Yusuf S, Xie C et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. The New England Journal of Medicine, 2007, 357(3): 217-27.

31. Andreotti F, Testa L, Biondi-Zoccai GG et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. European Heart Journal, 2006, 27(5): 519-26.

32. WAVE-Investigators. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. American Heart Journal, 2006, 151(1): 1-9.

33. Aboyans V, Ricco J-B, Bartelink M-L, Bjo¨rck M, Brodmann M. 2017 ESC Guidelines on the Diagnosis andTreatment of Peripheral Arterial Diseases,in collaboration with the European Societyfor Vascular Surgery (ESVS). European Heart Journal, 2017, 00: 1–60.

34. Alonso-Coello P, Bellmunt S, McGorrian C et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest, 2012, 141.

35. Duncan D, Wijeysundera D. Preoperative Cardiac evaluation and management of the patient undergoing major vascular surgery. International Anesthesiology Clinics, 2016, 54(2): 1-32.

36. IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter Instruction for Use.

37. Zilver PTX™ Drug Eluting Stent Instruction for Use.